Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s
about
Clinical trials of new drugs for the treatment of rheumatoid arthritis: focus on early diseasePatient reported outcomes in rheumatoid arthritis clinical trialsEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateEffect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trialsComparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression AnalysisTNF inhibitor therapy for rheumatoid arthritisBiologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Coronary Artery Disease Evaluation in Rheumatoid Arthritis (CADERA): study protocol for a randomized controlled trial.Adalimumab with Methotrexate in Treatment-Naïve Japanese Patients with Rheumatoid Arthritis at Risk of Progressive Structural Joint Damage: A Postmarketing Observational StudyAdalimumab, a human anti-TNF monoclonal antibody, outcome study for the prevention of joint damage in Japanese patients with early rheumatoid arthritis: the HOPEFUL 1 study.Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years.Cryotherapy in inflammatory rheumatic diseases: a systematic review.Two dosing regimens of certolizumab pegol in patients with active rheumatoid arthritisMaintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosisBiologic-free remission of established rheumatoid arthritis after discontinuation of abatacept: a prospective, multicentre, observational study in Japan.Risk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs.Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trialAttainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in methSafety and Efficacy of Methotrexate in Psoriasis: A Meta-Analysis of Published Trials.Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials.Comprehensive disease control (CDC): what does achieving CDC mean for patients with rheumatoid arthritis?The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.Adalimumab discontinuation in patients with early rheumatoid arthritis who were initially treated with methotrexate alone or in combination with adalimumab: 1 year outcomes of the HOPEFUL-2 study.Rheumatoid arthritis--early diagnosis and disease managementLong-term treatment of rheumatoid arthritis with adalimumab.Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis.Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis.Discontinuation of adalimumab after attaining disease activity score 28-erythrocyte sedimentation rate remission in patients with rheumatoid arthritis (HONOR study): an observational studyLow disease activity for up to 3 years after adalimumab discontinuation in patients with early rheumatoid arthritis: 2-year results of the HOPEFUL-3 Study.Recovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trial.Newest clinical trial results with antitumor necrosis factor and nonantitumor necrosis factor biologics for rheumatoid arthritisWhat is the evidence for the presence of a therapeutic window of opportunity in rheumatoid arthritis? A systematic literature review.Impact of biologic therapy on functional status in patients with rheumatoid arthritis--a meta-analysis.Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis.Induction therapy with combination TNF inhibitor and methotrexate in early rheumatoid arthritis.
P2860
Q26753120-F55A7F88-A0DF-40A4-8D2F-2AC5785E33E6Q26852960-19DCB52B-BA83-439A-B702-31AC4573DE12Q26859134-8983D42E-7B87-43CA-9D4A-EB2FBD780076Q28543128-CBB0CF3D-F582-4FA0-A374-C3D11AB6603FQ28547851-E08CB890-BD47-4F22-BE14-807EF2BF4491Q28972424-BDB19C1D-717A-47D0-BDCE-8B0AC4CEB521Q30234528-91B7A1F1-8296-4F5E-89B0-23A6C937462AQ30235341-08C539B6-5758-47AF-8CD7-DD4B0259D633Q30240183-286209EB-2450-457A-8AAF-014C1AA10B59Q30240212-2537E3DD-C22B-4715-9DDE-0D1AA5B6B028Q30426026-AC5A1268-B088-4249-AADC-06B80DFC5826Q33725547-E8A65F24-52F2-4AC2-B7F8-8F5D559621EFQ34118958-E478FE58-2C48-40D7-86A2-C6B1678F8B50Q34169347-7A445E35-08C9-4429-8223-5B0CECEDC6B4Q35068804-044B72C7-9ACF-4A60-A6D9-CEFEF1782135Q35086227-9E9C33B0-757B-49E7-8FED-036DDC8F0178Q35135825-B77A28DC-D277-442A-AF6E-2C6C311A60AEQ35214632-DB1AAC20-64F9-4ABB-A6A6-DE2065ABE537Q35237316-D81AAFD0-C0E4-4A8F-9525-24F70F6960A0Q35605449-D58087E2-A403-4C63-913E-48D9043E685CQ35827953-B960A2AD-6032-45A1-83E4-7B76ECD0219AQ36014642-8806011E-3E4C-489C-BDBA-7B5B2D1DBF95Q36195284-3EC1169F-8E24-4E40-9F03-5DB12579C93DQ36321264-125E89BC-4925-4EBB-BDD5-73847F7763A7Q36374666-933C28ED-D32F-4A18-AB80-E182F885ACFDQ36475622-B7E98B1E-A313-4D4F-94AD-F6D763B201F1Q36603276-D48D0FE3-7A15-472A-A0D7-6B976FEFAFBFQ37043713-7E1770F7-A19A-4D2A-8A2F-F9A21D9D87FAQ37358278-F16BEF46-D863-45E5-B91F-A75C7DABE50AQ37567461-FCA1AB7D-31F2-484A-A51F-FCE6A2ABA700Q37587412-0D43779D-317C-427A-B164-8E46EB28C39DQ37616969-FA6221BC-60AF-47B4-802A-90DADCEA8338Q37690027-09015227-21AD-4859-A556-438984DBFBA3Q37697988-BD45593D-9857-42D3-968D-EAD4BFE2882EQ37706297-BD085756-8032-4B32-87DD-ED3A43CE4A76Q38091288-C04A10EF-6D86-4CFF-933D-651FFE142015Q38097740-576F7564-21EA-4447-8F14-0F7D7EDC65A0Q38129036-F819A881-1647-4CDF-B59F-DB3FD20CE8B1Q38176549-53C34B45-7D8B-4EE0-AD21-96B0E7F539A4Q38195248-180C0AE2-2421-482E-861D-AD7B521AA70E
P2860
Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA s
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Clinical, functional and radio ...... andomised, controlled OPTIMA s
@ast
Clinical, functional and radio ...... andomised, controlled OPTIMA s
@en
Clinical, functional and radio ...... andomised, controlled OPTIMA s
@en-gb
type
label
Clinical, functional and radio ...... andomised, controlled OPTIMA s
@ast
Clinical, functional and radio ...... andomised, controlled OPTIMA s
@en
Clinical, functional and radio ...... andomised, controlled OPTIMA s
@en-gb
prefLabel
Clinical, functional and radio ...... andomised, controlled OPTIMA s
@ast
Clinical, functional and radio ...... andomised, controlled OPTIMA s
@en
Clinical, functional and radio ...... andomised, controlled OPTIMA s
@en-gb
P2093
P2860
P1476
Clinical, functional and radio ...... andomised, controlled OPTIMA s
@en
P2093
Arthur Kavanaugh
Benoit Guerette
Hartmut Kupper
Laura Redden
Roy M Fleischmann
Sourav Santra
P2860
P356
10.1136/ANNRHEUMDIS-2011-201247
P407
P577
2012-05-05T00:00:00Z
P5875
P6179
1002818532